Dr. Mark Archie, MD
Claim this profileHarbor-UCLA Medical Center
Studies Arterial Occlusive Disease
Studies Peripheral Arterial Disease
3 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Mark Archie, MD is currently running
Decellularized Femoral Artery Transplant
for Chronic Kidney Failure
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
Recruiting1 award N/A5 criteria
Endovascular Repair
for Aortic Disease
This is an early feasibility study that investigates the outcome of selected patients with complex thoracoabdominal aortic lesions who are suitable for endovascular (within the vessel) repair with a physician-modified Medtronic Thoracic Valiant stent graft. The Medtronic Valiant System includes a Valiant Thoracic Stent Graft, a self-expanding, tubular end prosthesis which is modified/customized by the Investigators to fit the patient's anatomy. The device is constructed by making a taper in the larger proximal thoracic device and attaching it to a smaller distal thoracic device. The Viabahn branches for the visceral vessels are sutured to holes made in the tapered section. The modified Valiant stent graft is advanced to the lesion site endoluminally via the iliac/femoral artery. Access for delivery of extensions to the device will be delivered through the left subclavian artery. Upon deployment, the stent graft self-expands at the target location, where it is designed to exclude the lesion by restoring blood flow through the stent graft lumen.
Recruiting1 award N/A6 criteria
More about Mark Archie, MD
Clinical Trial Related4 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mark Archie, MD has experience with
- LimFlow System
- Nexeon AVX Decellularized Femoral Artery
- Physician Modified Endovascular Prosthesis
Breakdown of trials Mark Archie, MD has run
Arterial Occlusive Disease
Peripheral Arterial Disease
Arteriosclerosis
Peripheral Artery Disease
Critical Limb Ischemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Archie, MD specialize in?
Mark Archie, MD focuses on Arterial Occlusive Disease and Peripheral Arterial Disease. In particular, much of their work with Arterial Occlusive Disease has involved treating patients, or patients who are undergoing treatment.
Is Mark Archie, MD currently recruiting for clinical trials?
Yes, Mark Archie, MD is currently recruiting for 2 clinical trials in Torrance California. If you're interested in participating, you should apply.
Are there any treatments that Mark Archie, MD has studied deeply?
Yes, Mark Archie, MD has studied treatments such as LimFlow System, Nexeon AVX Decellularized Femoral Artery, Physician Modified Endovascular Prosthesis.
What is the best way to schedule an appointment with Mark Archie, MD?
Apply for one of the trials that Mark Archie, MD is conducting.
What is the office address of Mark Archie, MD?
The office of Mark Archie, MD is located at: Harbor-UCLA Medical Center, Torrance, California 90502 United States. This is the address for their practice at the Harbor-UCLA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.